|
1
|
Reya T, Morrison SJ, Clarke MF and
Weisssman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park CH, Bergsagel DE and McCulloch EA:
Mouse myeloma tumor stem cells: a primary cell culture assay. J
Natl Cancer Inst. 46:411–422. 1971.PubMed/NCBI
|
|
3
|
Gupta PB, Chaffer CL and Weinberg RA:
Cancer stem cells: mirage or reality? Nat Med. 15:1010–1012. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Merlos-Suárez A, Barriga FM, Jung P, et
al: The intestinal stem cell signature identifies colorectal cancer
stem cells and predicts disease relapse. Cell Stem Cell. 8:511–524.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fletcher JI, Haber M, Henderson MJ and
Norris MD: ABC transporters in cancer: more than just drug efflux
pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin Y, Bin ZQ, Qiang H, et al: ABCG2 is
related with the grade of glioma and resistance to mitoxantone, a
chemotherapeutic drug for glioma. J Cancer Res Clin Oncol.
135:1369–1376. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang B, Yang H, Huang YZ, Yan RH, Liu FJ
and Zhang JN: Biologic characteristics of the side population of
human small cell lung cancer cell line H446. Chin J Cancer.
29:254–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adhikari AS, Agarwal N, Wood BM, et al:
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells
associated with metastasis and drug resistance. Cancer Res.
70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu L, McArthur C and Jaffe RB: Ovarian
cancer stem-like side-population cells are tumourigenic and
chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tokar EJ, Qu W, Liu J, et al:
Arsenic-specific stem cell selection during malignant
transformation. J Natl Cancer Inst. 102:638–649. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Guo LP, Chen LZ, Zeng YX and Lu
SH: Identification of cancer stem cell-like side population cells
in human nasopharyngeal carcinoma cell line. Cancer Res.
67:3716–3724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu C, Li H, Li J, et al: Analysis of ABCG2
expression and side population identifies intrinsic drug efflux in
the HCC cell line MHCC-97L and its modulation by Akt signaling.
Carcinogenesis. 29:2289–2297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Allen JD, van Loevezijn A, Lakhai JM, et
al: Potent and specific inhibition of the breast cancer resistance
protein multidrug transporter in vitro and in mouse intestine by a
novel analogue of fumitremorgin C. Mol Cancer Ther. 1:417–425.
2002.PubMed/NCBI
|
|
15
|
Cisternino S, Mercier C, Bourasset F, Roux
F and Scherrmann JM: Expression, up-regulation, and transport
activity of the multidrug-resistance protein Abcg2 at the mouse
blood-brain barrier. Cancer Res. 64:3296–3301. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qin XQ, Liang YG, Gao HZ, et al: Reversing
mechanism of schizandrin A on multi-drug resistance of K562/ADR,
HL60/ADR, MCF-7/ADR cell lines. Chin Pharmacol Bull. 27:329–334.
2011.
|
|
17
|
Huang M, Jin J, Sun H and Liu GT: Reversal
of P-glycoprotein-mediated multidrug resistance of cancer cells by
five schizandrins isolated from the Chinese herb Fructus
Schizandrae. Cancer Chemother Pharmacol. 62:1015–1026. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slaninová I, Brezinová L, Koubíková L and
Slanina J: Dibenzocyclooctadiene lignans overcome drug resistance
in lung cancer cells - study of structure-activity relationship.
Toxicol In Vitro. 23:1047–1054. 2009. View Article : Google Scholar
|
|
19
|
Chai S, To KK and Lin G: Circumvention of
multi-drug resistance of cancer cells by Chinese herbal medicines.
Chin Med. 5:262010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gupta PB, Onder TT, Jiang G, et al:
Identification of selective inhibitors of cancer stem cells by
high-throughput screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Riccioni R, Dupuis ML, Bernabei M, et al:
The cancer stem cell selective inhibitor salinomycin is a
p-glycoprotein inhibitor. Blood Cells Mol Dis. 45:86–92. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma I and Allan AL: The role of human
aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell
Rev. 7:292–306. 2011. View Article : Google Scholar
|
|
23
|
Croker AK and Allan AL: Inhibition of
aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and
radiation resistance of stem-like ALDHhiCD44+ human
breast cancer cells. Breast Cancer Res Treat. 133:75–87. 2012.
View Article : Google Scholar
|
|
24
|
Chen YC, Chen YW, Hsu HS, et al: Aldehyde
dehydrogenase 1 is a putative marker for cancer stem cells in head
and neck squamous cancer. Biochem Biophys Res Commun. 385:307–313.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Januchowski R, Wojtowicz K and Zabel M:
The role of aldehyde dehydrogenase (ALDH) in cancer drug
resistance. Biomed Pharmacother. 67:669–680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kakarala M, Brenner DE, Korkaya H, et al:
Targeting breast stem cells with the cancer preventive compounds
curcumin and piperine. Breast Cancer Res Treat. 122:777–785. 2010.
View Article : Google Scholar
|
|
27
|
Li Y, Zhang T, Korkaya H, et al:
Sulforaphane, a dietary component of broccoli/broccoli sprouts,
inhibits breast cancer stem cells. Clin Cancer Res. 16:2580–2590.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cioce M, Gherardi S, Viglietto G, et al:
Mammosphere-forming cells from breast cancer cell lines as a tool
for the identification of CSC-like- and early progenitor-targeting
drugs. Cell Cycle. 9:2878–2887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wickström M, Danielsson K, Rickardson L,
et al: Pharmacological profiling of disulfiram using human tumor
cell lines and human tumor cells from patients. Biochem Pharmacol.
73:25–33. 2007. View Article : Google Scholar
|
|
30
|
Calabrese C, Poppleton H, Kocak M, et al:
A perivascular niche for brain tumor stem cells. Cancer Cell.
11:69–82. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Atsumi N, Ishii G, Kojima M, Sanada M,
Fujii S and Ochiai A: Podoplanin, a novel marker of
tumor-initiating cells in human squamous cell carcinoma A431.
Biochem Biophys Res Commun. 373:36–41. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He X, Marchionni L, Hansel DE, et al:
Differentiation of a highly tumorigenic basal cell compartment in
urothelial carcinoma. Stem Cells. 27:1487–1495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colmone A, Amorim M, Pontier AL, Wang S,
Jablonski E and Sipkins DA: Leukemic cells create bone marrow
niches that disrupt the behavior of normal hematopoietic progenitor
cells. Science. 322:1861–1865. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lane SW, Scadden DT and Gilliland DG: The
leukemic stem cell niche: current concepts and therapeutic
opportunities. Blood. 114:1150–1157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vermeulen L, De Sousa E, Melo F, van der
Heijden M, et al: Wnt activity defines colon cancer stem cells and
is regulated by the microenvironment. Nature Cell Biol. 12:468–476.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Basak GW, Srivastava AS, Malhotra R and
Carrier E: Multiple myeloma bone marrow niche. Curr Pharm
Biotechnol. 10:345–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ostman A: The tumor microenvironment
controls drug sensitivity. Nat Med. 18:1332–1334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vinogradov S and Wei X: Cancer stem cells
and drug resistance: the potential of nanomedicine. Nanomedicine
(Lond). 7:597–615. 2012. View Article : Google Scholar
|
|
39
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Segers J, Di Fazio V, Ansiaux R, et al:
Potentiation of cyclophosphamide chemotherapy using the
anti-angiogenic drug thalidomide: importance of optimal scheduling
to exploit the ‘normalization’ window of the tumor vasculature.
Cancer Lett. 244:129–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Horsman MR and Siemann DW:
Pathophysiologic effects of vasculartargeting agents and the
implications for combination with conventional therapies. Cancer
Res. 66:11520–11539. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: at the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
46
|
Rattan R, Ali Fehmi R and Munkarah A:
Metformin: an emerging new therapeutic option for targeting cancer
stem cells and metastasis. J Oncol. 2012:9281272012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: an emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tang SN, Fu J, Nall D, Rodova M, Shankar S
and Srivastava RK: Inhibition of sonic hedgehog pathway and
pluripotency maintaining factors regulate human pancreatic cancer
stem cell characteristics. Int J Cancer. 131:30–40. 2012.
View Article : Google Scholar :
|
|
49
|
Song Z, Yue W, Wei B, et al: Sonic
hedgehog pathway is essential for maintenance of cancer stem-like
cells in human gastric cancer. PLoS One. 6:e176872011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Merchant AA and Matsui W: Targeting
Hedgehog - a cancer stem cell pathway. Clin Cancer Res.
16:3130–3140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Singh BN, Fu J, Srivastava RK and Shankar
S: Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits
pancreatic cancer stem cell characteristics: molecular mechanisms.
PLoS One. 6:e273062011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xia J, Chen C, Chen Z, Miele L, Sarkar FH
and Wang Z: Targeting pancreatic cancer stem cells for cancer
therapy. Biochim Biophys Acta. 1826:385–399. 2012.PubMed/NCBI
|
|
53
|
Fan X, Khaki L, Zhu TS, et al: NOTCH
pathway blockade depletes CD133-positive glioblastoma cells and
inhibits growth of tumor neurospheres and xenografts. Stem Cells.
28:5–16. 2010.
|
|
54
|
Kondratyev M, Kreso A, Hallett RM, et al:
Gamma-secretase inhibitors target tumor-initiating cells in a mouse
model of ERBB2 breast cancer. Oncogene. 31:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Takahashi-Yanaga F and Kahn M: Targeting
Wnt signaling: can we safely eradicate cancer stem cells? Clin
Cancer Res. 16:3153–3162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sarkar FH, Li Y, Wang Z, Kong D and Ali S:
Implication of microRNAs in drug resistance for designing novel
cancer therapy. Drug Resist Updat. 13:57–66. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Arrieta O, González-De la Rosa CH,
Aréchaga-Ocampo E, et al: Randomized phase II trial of
all-trans-retinoic acid with chemotherapy based on paclitaxel and
cisplatin as first-line treatment in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 28:3463–3471. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sze CI, Su WP, Chiang MF, Lu CY, Chen YA
and Chang NS: Assessing current therapeutic approaches to decode
potential resistance mechanisms in glioblastomas. Front Oncol.
3:592013. View Article : Google Scholar : PubMed/NCBI
|
